Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

NCT06341764 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: Durvalumab 1120 mg
DRUG: Durvalumab 1500 mg
DRUG: Tremelimumab i.v. at 300 mg
COMBINATION_PRODUCT: Cisplatin (CDDP) 25 mg/mq i.v
COMBINATION_PRODUCT: Gemcitabine (GEM) 1000 mg/mq i.v.

Sponsor

National Cancer Institute, Naples